Care map information Quick info:
Scope:
• assessment and emergency management of acute heart failure (HF) in adults age 18 years and older
• diagnosis, assessment, and management of chronic HF in adults age 18 years and older
Out of scope:
• assessment and management of HF in:
• children and adolescents under age 18 years
• pregnant women
• management of specific causes of HF Definition [3] :
• HF is a complex clinical syndrome of symptoms and signs that suggest impairment of the heart as a pump supporting physiological circulation • caused by structural or functional abnormalities of the heart Classification (NYHA): New York Heart Association (NYHA) class used in pathway (see classification node) Potential causes include:
• conditions that damage heart muscle or limit its ability to function normally, such as:
• coronary artery disease (CAD) − accounts for about two-thirds of all systolic HF cases [4] • hypertension [4] • cardiomyopathies [4] • endocrine conditions, eg:
• diabetes mellitus • conditions that reduce cardiac output, such as:
• increased vascular resistance with hypertension
• abnormal heart rhythm, eg atrial fibrillation (AF)
• aortic stenosis (severe)
• severe mitral regurgitation pericardial disease [4] • obstructive sleep apnoea (OSA)
• conditions that result in a high cardiac output, such as:
• anaemia [4, 5] • thyrotoxicosis [4, 5] • septicaemia [4, 5] • liver failure Published: 18-Feb-2016 Valid until: 17-Nov-2017 • arteriovenous shunts [4, 5] • Paget's disease of the bone [4, 5] • thiamine (vitamin B1) deficiency [4, 5] • medications that may exacerbate heart failure, such as:
• agents that can adversely affect conduction, eg anti-arrhythmic agents, heart-rate slowing calcium-channel blockers, and beta-blockers • some calcium-channel blockers that are negatively inotropic, eg nifedipine, verapamil, diltiazem
• toxins, eg:
• alcohol
• mercury
• cobalt
• arsenic
• cocaine
Incidence and prevalence:
• around 300,000 (1.5-2%) Australians are living with HF, with around 30,000 diagnosed each year [1, 2] .
• both incidence and prevalence of HF increase steeply with age [3] . Prevalence is expected to rise through a combination of:
• improved survival of people with ischaemic heart disease (IHD)
• more effective treatments for HF
• an ageing population
• among Aboriginal and Torres Strait Islander people, chronic heart failure is 1.7 times more common, occurs at a younger age, and rate of preventable CHF related hospitalisations is three times higher than among non-indigenous Australians [2] • more than 45,000 Australians were hospitalised with heart failure between 2009-2010, equating to more than 360,000 bed-days [1] • two thirds of CHF hospitalisations in Australia are considered to be preventable
• between 20-27%people with HF will be readmitted to hospital within one month of being discharged [1, 2] • CHF and complications arising are in the top five ambulatory care sensitive conditions in the Frankston Mornington Peninsula catchment • HF currently accounts for
• 2% of all hospitalised bed-days • 5% of all medical emergency admissions (check aust data) Prognosis (Australian Heart Foundation statistics):
• 20-30% of patients diagnosed with mild-moderate HF, and 50% of people diagnosed with severe HF die within one year [1] • prognosis for people with HF and preserved left ventricular ejection fraction (LVEF) is a little better than for people with HF and reduced ejection fraction • younger patients tend to do better, as do patients with no co-morbidities [3] 3 Key Messages Quick info:
Best management of CHF reduces mortality & morbidity with reduced hospitalisation and better quality of life. Echocardiography is the best test for diagnosis and assessment of heart failure. Classification into systolic vs diastolic, and severity of heart failure, guides management and prognosis. Treatment of comorbidities such as anaemia improves CHF symptoms. Lifestyle educatiion-exercise; salt reduction, fluid monitoring & weight management improves outcomes-consider HF rehabilitation services and Chronic disease management medicare items. Avoid/cease drugs that worsen CHF. Prescribe
• diuretics for fluid overload
• ACEI for all SHF-"start low go slow"
• specific beta blockers titrated to highest doses for moderate/severe CHF • then titrate ACEI to effective doses
• digoxin & nitrates & fish oil may help symptoms
• spironolactone may be added for severe SHF Refer to specialists early for severe, complicated or non responsive CHF, or where comorbidities affect management. The quick reference guide derived from the Heart Foundation guidelines for management of heart failure summarises the key messages for heart failure management; CHF guide . The Heart Foundation fact sheet summarises the evidence supporting the need for optimal management of heart failure in Primary Care. Published: 18-Feb-2016 Valid until: 17-Nov-2017 Systolic Heart Failure (also called Left ventricular systolic dysfunction -LVSD) may be symptomatic or asymptomatic [3] . SHF:
• just over half of all heart failure (HF) patients are found to have LVSD on echocardiography, i.e. reduced left ventricular ejection fraction (LVEF) • there is no agreement on what level should be used to separate normal from abnormal LVEF − the usual cut-off is approximately 40−50%
• most people with reduced LVEF also have diastolic dysfunction Management of SHF:
• aims of treatment are to [3] :
• relieve symptoms and signs and improve quality of life (QoL)
• prevent hospital admission
• improve survival
• the three principle treatment approaches involve:
• lifestyle modifications [1] • targeted pharmacological treatment [1] • treatment of co-morbidities [3] • non-pharmacological intervention may need to be considered depending on response to treatment and co-morbidities [1] References: 1. National Clinical Guideline Centre (NCGC). Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care: full version of NICE clinical guideline no 108. London: NCGC at the Royal College of Physicians; 2010. 2. National Heart Foundation. Guidelines for the prevention, detection and management of heart failure in Australia. 2011. 3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847. 6 Diastolic Heart Failure (= Heart Failure with Preserved Systolic Function -HFPSF)
Quick info:
Diastolic Heart Failure ( heart failure with preserved systolic function -HFPSF) is the failure of the left ventricle to relax sufficiently to fill during diastole, or increased myocardial stiffness resulting in higher fillingpressures. It is important to distinguish this from systolic heart failure as management and prognosis are distinctly different. Associated with
• hypertension,
• ischaemic heart disease,
• diabetes mellitus,
• valvular disease,
• hypertrophic and restrictive cardiomyopathies and • more commonly in older females possibly with age related fibrosis.
Diagnosis is with echocardiography with LVEF of >45%. Gated pool scanning or direct left ventriculography may also show this. This, combined with symptoms & signs of CHF, make the diagnosis probable. There is no current role for BNP in diagnosis or management.
Prognosis is for lower short term mortality than for SHF, but mortality is still high, with hospitalisation rates similiar to SHF.
Reference:
National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011 Published: 18-Feb-2016 Valid until: 17-Nov-2017 Refer patients to the heart failure specialist [1] :
• if the initial diagnosis of HF is uncertain;
• for HF that does not respond to treatment
• for HF not tolerating medical management eg hypotension
• for HF that can no longer be managed effectively in the home setting
• patients who are planning a pregnancy, or who are pregnant Consider referral to a specialist for patients with HF and a co-morbidity that is:
• severe
• contributing significantly to HF in the patient
• complicating the management of HF Specialist advice may be appropriate for some patients with HF and a co-morbidity, such as:
• angina
• atrial fibrillation or other symptomatic arrhythmia Refer patients to the heart failure specialist [1] :
• for management of severe HF -New York Heart Association (NYHA) class IV
• patients who are planning a pregnancy, or who are pregnant Consider referral for assessment for cardiac resynchronisation therapy (CRT) and an implantable cardioverter defibrillator (ICD), for patients who meet either of the following criteria:
• left ventricular (LV) ejection fraction 35% or less, and previous myocardial infarction (MI); or There are still no conclusive data regarding the efficacy of any drug class in treating diastolic heart falure (HFPSF)
• diuretics, and salt & fluid restriction are used to treat acute symptoms of pulmonary congestion and peripheral oedema with care to avoid hypovolaemia due to this groups sensitivity to change in blood volume due to reduced LV compliance.
• cease exacerbating drugs: NSAIDS, Calcium Channel Blockers and B Blockers -other than bisoprolol, carvedilol & metoprolol extended release (i.e.succinate)(see extensive list in node under Severe HF) Suggested treatments for diastolic heart failure:
• aggressive risk-factor modification, including:
• blood pressure reduction, particularly using ACEI or ARB to reduce LV hypertrophy and • glycaemic control [2] • there may be no direct reversal of diastolic dysfunction with this management
• AF-Ventricular rate needs control to maximise LV filling time.
• coronary heart disease is common in this group and should be sought and managed.
A study evaluating the effects of perindopril (an ACEI) in patients with HFPSF, reported in 2006, had insufficient power to determine its effects on long-term morbidity and mortality [3] . A later study found that angiotensin II receptor blockade with irbesartan did not improve outcomes for patients with HFPSF [4] . Arrange Domiciliary or Residential Medicine Review Regular physical activity is strongly advised for people with CHF, with benefits including a reduction in physical deconditioning, symptoms and neurohormonal abnormalities, as well as improvements in functional capacity, however it is not clear if this benefit extends to patients with Diastolic Heart Failure. References: 1. Krum H, Jelinek HV, Stewart S, Sindone A, Atherton JJ. 2011 Update to Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006 . Med J Aust 2011 194 (8) : 405-409. • New York Heart Association (NYHA) class I:
• includes asymptomatic left ventricular dysfunction
• ordinary physical activity does not cause fatigue, breathlessness, or palpitations
• NYHA class II:
• symptomatically 'mild' heart failure • slight limitation of physical activity
• ordinary physical activity may result in fatigue, palpitations, breathlessness, or angina pectoris
• NYHA class III:
• symptomatically 'moderate' HF
• marked limitation with physical activity
• patient is comfortable at rest, but ordinary physical activity will lead to symptoms
• NYHA class IV:
• symptomatically 'severe' HF • inability to carry out physical activity without discomfort
• symptoms of cardiac failure are present even at rest Reference; National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011.
Essential non pharmacological management (all classes)
Quick info:
For presentation, diagnosis, investigation and differential diagnosis see "Heart Failure Suspected " page 15 Severe / Moderate / Mild heart failure (HF) NYHA class IV , III, II
Quick info:
Severe heart failure (HF) characterised by;
• symptomatically severe HF inability to carry out physical activity without discomfort
• symptoms of cardiac failure present at rest Echocardiogram may report ejection fraction <40% Mild-moderate HF presents as;
• mild to marked limitation with physical activity
• comfortable at rest but ordinary physical activity may result in fatigue, palpitations, breathlessness or angina • New York Heart Association (NYHA) class I:
16 Asymptomatic heart failure (HF) NYHA class I Quick info:
New York Heart Association (NYHA) class I:
• Ordinary physical activity does not cause fatigue, breathlessness, or palpitations
• prevalence of asymptomatic LVSD is 3% of the general population [4] • the mean age of patients with asymptomatic LVSD is lower than that of symptomatic patients [4] • patients are at increased risk of having a cardiovascular event [4] • patients with untreated asymptomatic LVSD have an 8% risk of developing HF symptoms annually [3] Management of asymptomatic LVSD:
• lifestyle modifications
• vigorous management of risk factors, eg ischaemic heart disease (IHD) and hypertension
• pharmacological treatment targeted towards preventing disease progression 
Management of co-morbidity with HF Quick info:
Specialist referral is recommended where co-morbidities exist with heart failure. Co-morbidities are important in patients with heart failure (HF) because [2] :
• existing co-morbidities may affect treatments for HF
• medications used to treat co-morbidities may cause worsening of HF:
• such as non-steroidal anti-inflammatory drugs (NSAIDs) used to treat arthritis
• medications used to treat HF and those used to treat co-morbidities may interact with one another:
• such as beta-blockers and beta-agonists for chronic obstructive pulmonary disease (COPD) and asthma • the co-morbidity is:
• complicating the management of HF
• the GP does not have a special interest in the co-morbidity present Commence Beta blockers such as bisoprolol, carvedilol or metoprolol extended release (i.e.succinate), if ejection fraction (EF)<40%. Start low and increase to target doses if tolerated. Increase slowly to minimise hypotension; worsening of symptoms due to decreased sympathetic drive; and bradycardia. Side effects are often transitory and rarely need cessation of the B-blocker. Further increase the ACE inhibitor after the B-blocker has been maximised Aldosterone antagonists -spironolactone (average dose 25mg/day) reduce all cause mortality and symptoms in advanced CHF. Beware hyperkalaemia and warn of gynaecomastia.Use earlier if persistent oedema. Polyunsaturated fatty acids such as fish oil, added to management of symptomatic CHF, reduce mortality and hospital admissions. Recommend consuming 1gm eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). This can be achieved by eating two to three serves of 150 grams of oily fish every week and supplementing intake with fish oil and omega-3 enriched foods. Omega-3 detail Iron replacement with intravenous ferric carboxymaltose iron, improves symptoms & exercise tolerance in iron deficient patients. Further therapies that may be considered, usually at specialist care level, if HF is unresponsive -include [1]:
• aldosterone antagonist-eplerenone [1] • angiotensin II receptor blockers (ARBs), eg candesartan (in addition to ACEI) [1] • ivabradine [6] • digoxin [1] • hydralazine in combination with nitrate -particularly if the patient is of Afro-Caribbean origin and has moderate to severe heart failure [1] Oral anticoagulation therapy:
• other than in patients with atrial fibrillation (AF), there is no evidence that an oral anticoagulant reduces mortality or morbidity compared with placebo or aspirin [3] See also 'Medication cautions and interactions' node for co-morbidity medication management..
Pharmacological management Quick info:
If possible, cease medications that may be affecting the patient's heart failure (HF), eg: • should be used indefinitely in all patients with asymptomatic HF, unless intolerant
• reduce or prevent progression to symptomatic HF
• reduce hospitalisation and death from CHF.
• effective in reducing heart failure development in patients with coronary artery disease particularly post MI.
• Ramipril 10mg daily , enalapril (10mg twice daily) and perindopril have strong evidence.
• Start low and increase slowly as tolerated.
See node in adjacent Symptomatic HF path for further detail regarding dosing and monitoring.
Beta-blockers:
• limited evidence of reducing progression from asymptomatic to symptomatic HF.
• for post MI patients with CHF reduces all-cause and cardiovascular mortality, and recurrent non-fatal MI.
• See node in adjacent Symptomatic HF path for further detail regarding dosing and monitoring. • Hypertension-is a major risk factor, and its control is more important than the agent used. Add a second or third agent if needed • Statins to prevent ischaemic events and subsequent CHF in patients who fulfil criteria for lipid lowering.
• Aspirin should be considered in patients with Coronary Heart Disease.
Reference NHF Australia 22 Physical activity and rehabilitation
Quick info:
Regular physical activity is strongly advised for people with CHF, with benefits including a reduction in physical deconditioning, symptoms and neurohormonal abnormalities, as well as improvements in functional capacity. 3 The evidence supporting the benefits of regular physical activity in people with CHF, particularly among middle-aged patients with systolic heart failure, has strengthened in recent years.
• Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) showed that aerobic exercise, in addition to usual care, resulted in improvements in self-reported health status, including quality of life, in patients with heart failure and a left-ventricular ejection fraction (LVEF) ≤ 35%.10
• A retrospective analysis of the study (adjusted for prognostic factors) showed that patients who exercised as instructed achieved modest but significant benefits in terms of clinical outcomes (including all-cause mortality or hospitalisation and cardiovascular mortality or hospitalisation for CHF).11 The recommendation in the 2006 guidelines that all patients be referred to a specifically designed physical activity program, if available, stands (Grade A recommendation). Uncertainty remains about the benefit of physical activity in older patients and those with CHF associated with preserved leftventricular systolic function. 
References-

Ischaemic heart disease (IHD) with SHF Quick info:
Ischaemic heart disease (IHD) with systolic heart failure:
• is best managed in conjunction with a cardiologist
• IHD is a common cause of HF, and people with HF often have IHD
Pharmacological management considerations:
• beta-blockers [3] :
• recommended for angina as well as an essential treatment for systolic HF
• nitrates :
• have a good safety profile for use in HF
• should be initiated by a specialist • contraindicated in unstable or acute HF [4] • ivabradine [3] :
• considered to be a safe anti-anginal treatment for patients with HF • are effective at controlling angina symptoms, but some may aggravate HF • consider amlodipine [1] • do not use verapamil, diltiazem, and short-acting dihydropyridine [1] • aldosterone antagonists [5] :
• eplerenone has been demonstrated to significantly improve outcomes when combined with an ACEI and beta-blocker in patients with LVSD following myocardial infarction (MI) • aspirin [1] :
• for patients with HF and atherosclerotic arterial disease (including coronary heart disease)
• statins:
• should be commenced according to normal practice in IHD,
• use in HF and asymptomatic coronary artery disease remains controversial
• The safety of other anti-anginal drugs such as nicorandil and ranolazine is uncertain [3] .
Coronary revascularisation [3]:
• percutaneous and surgical revascularisation are alternative approaches to the treatment of angina • heart failure (HF) rehab and multidisciplinary care is highly beneficial
• key areas to explain;
• pathogenesis/prognosis
• medication effects, titration, side effects and interactions
Effective communication is key to successful HF management and is likely to increase patient compliance with therapy [1] . All management decisions should be discussed with the patient and viewed as shared decisions between both the patient and the GP [1] . When communicating with the patient [1] :
• provide explanations in a manner appropriate to the individual • patients should be encouraged to self-manage their condition where appropriate
• some patients, with appropriate education, can monitor their own volume status by regular weighing and adjusting their diuretic therapy accordingly [1] :
• this requires easy access to the HF rehabilitation team [1] • ensure that the patient or their carer knows:
• how to adjust the dose in response to symptoms
• when to seek help if their symptoms deteriorate or fail to respond to dose adjustment
• inform the patient that they can adjust the times that they take the diuretic to suit social needs, eg if they are going out, they can delay a dose until they return Multidisciplinary care:
• the approach to management should be multidisciplinary, involving primary, secondary, and community care professionals [1] • should target high-risk symptomatic patients [3] Published • should be routinely used for the relief of congestive symptoms and fluid retention in patients with heart failure (HF) [1] • effect depends on good renal function, ie creatinine clearance greater than 40mL/minute
• aim for an increase in urine production & weight loss of 0.5-1kg daily
Loop diuretics:
• preferred diuretics in HF as they have a more powerful effect than thiazides
• include frusemide, bumetanide
• the most beneficial of the diuretics as they:
• increase sodium and free water excretion
• maintain this effect even when there is slight renal impairment
Thiazide-type diuretics:
• cause more gentle and prolonged diuresis than loop diuretics [3] • include hydrochlorothiazide, bendrofluazide, chlorthalidone or indapamide
• consider prescribing if patient:
• is hypertensive with only mild symptoms [4] • has resistant oedema:
• may be added (with caution) to treatment with a loop diuretic
• may be given in primary care under specialist supervision
• use with caution when prescribing a thiazide and loop diuretic as the combination can cause severe diuresis and dehydration, hyponatraemia, hypovolaemia, and hypokalaemia Potassium-sparing diuretics (eg spironolactone):
• not generally recommended due to the risk of severe hyperkalaemia in combination with other drugs used in HF
• may be used in secondline treatment of HF
• seek specialist advice before initiating in primary care [1] • see later node "Consider Spironolactone"
Commencing treatment:
• loop diuretics are usually given once a day in the morning, but can be given twice a day (morning and lunchtime) for additional diuresis • the patient can adjust the timing of the doses to suit their social needs • use the lowest dose possible to control symptoms • review and adjust the dose according to:
• symptoms
• signs of congestion
• weight loss
• after subsequent treatment for HF has been introduced • provide education regarding self-adjustment of the dose based on regular weight measurements and other signs and symptoms of fluid retention Refer for specialist advice if doses of more than 80mg frusemide daily are necessary [1] .
Adverse effects of excessive diuresis may include:
• orthostatic hypotension • HF rehab programmes have been shown to improve exercise capacity and quality of life for people with heart failure • physical activity within ability:
• encourage regular aerobic exercise to improve functional capacity and symptoms [2] • reduces thromboembolic risk and other consequences of prolonged bed rest
• healthy weight and dietary restrictions:
• limit salt intake
• inform about the salt content of common food
• advise patients not to replace salt with salt substitutes that are high in potassium
• specific dietary advice may be indicated in certain patients, eg those with diabetes
• refer to a dietitian if:
• cachectic
• overweight
• advise patients to avoid excessive fluid intake:
• consider restricting to 1.5-2.0L per day in those with severe symptoms
• although experienced clinicians suggest restricting fluid intake to less than approximately 2.0L a day in patients with mild/ moderate symptoms, some International guidelines state that routine fluid restriction is probably not of benefit with these patients [2] • restriction of hypotonic fluids may improve hyponatraemia [2] • weight-based fluid restriction may cause less thirst [2] :
• 30mL/kg body weight; or • 35mL/kg if body weight greater than 85 kg
• smoking:
• all smokers should be encouraged to stop and offered assistance in smoking cessation
• an individual programme based on motivational assessment may include referral to smoking cessation services and nicotine replacement therapy [1] − see 'Smoking cessation' pathway • alcohol:
• discuss alcohol consumption with the patient and tailor advice appropriately to the clinical circumstances [1] • alcohol is contraindicated in those with alcohol related cardiomyopathy [1] • psychosocial aspects:
• depression and anxiety:
• the diagnosis of depression should be considered in all patients with HF [1] • where depression is likely to have been precipitated by HF symptoms, reassess the patient's psychosocial status once the physical condition has stabilised [1] • where it is apparent that depression is co-existing with HF, treat the patient for depression [1] • carefully consider the potential risks and benefits of medication treatment [1] ( see adjacent depression with LV dysfunction node) • a recent review of the evidence suggests a significant overall improvement in quality of life (QoL) after conducting psychosocial interventions [3] • travel and leisure:
• air travel − no restrictions are necessary in stable patients [1] • advise to carry a written report of medical history and current medication regimen, and carry extra medication [2] • monitor and adapt fluid intake, particularly during flights and in hot climates [2] • beware of adverse reactions to sun exposure with certain medications, eg amiodarone [2] • driving regulations:
• direct the patient to VicRoads guidelines including obligation of notifying Vicroads of a medical condition
• medical standards for assessing fitness to drive are on the AustRoads website • sexual activity − there are no specific restrictions; broach the subject in a sensitive manner as necessary and target advice towards the individual [1] Consider immunisation in all patients to minimise the risk of exacerbating chronic HF with respiratory infection [1] :
• advise an annual influenza vaccination
• offer pneumococcal vaccination, a second dose may be recommended • consider reducing the dose of ACEI or ARB to a previously tolerated lower dose
• recheck levels in 5-7 days If serum potassium persists above 6mmol/L despite these measures [4] • stop ACEI or ARBs
• consider referral to a dietitian [4] :
• a low-potassium diet (up to 2g daily) or dietary advice may help resolve hyperkalaemia Diuretics -monitoring during treatment: is the same as for ACEI above. Additionally for patients receiving a combination of a loop diuretic and a thiazide [4] :
• check renal function within 5 days of starting combination treatment and recheck every 5-14 days, depending on the patient's stability • monitor weight and hydration status -if diuresis is extensive, consider earlier testing of renal function
Diuretics -managing abnormal results:
If serum creatinine level increases by more than 20% or eGFR decreases by more than 15%, of baseline, re-measure renal function within 2 weeks [4] If serum creatinine increases by 30-50% (or to greater than 200micromol/L) or the eGFR is less than 30mL/min/1.73m2 [4] :
• review volume status
• reduce or stop diuretics (if the patient is hypovolaemic)
• re-measure renal function within 1 week If serum creatinine level increases by more than 50% or to greater than 256micromol/L (eGFR is approximately 20-25mL/ min/1.73m2) [4] :
• assess volume status
• check blood pressure (BP)
• review other renal function tests, including electrolytes and proteinuria
• if the patient is hypovolaemic, stop the diuretic; otherwise, manage accordingly
• seek specialist advice urgently if there is any uncertainty
Diuretics -managing hypokalaemia:
Patients at high risk of cardiac arrhythmias with even mild hypokalaemia include those [4] :
• taking digoxin or drugs that prolong the QT interval, eg amiodarone
• with paroxysmal arrhythmias, unstable angina, or chronic liver disease Potassium below 3mmol/L (or 4mmol/L in high-risk patients) [3, 4] :
• seek urgent specialist advice or consider admission [3] • review diuretic treatment [4] Potassium less than 2.5mmol/L (or 3.5mmol/L in high-risk patients)
• seek specialist advice urgently [4] for possible urgent admission for treatment. [3] • expert opinion suggests considering the use of potassium supplements or spironolactone [3, 26] 30 Hypertension or diabetes with SHF Quick info:
Hypertension and systolic heart failure:
• all patients with systolic heart failure should be prescribed an ACEI and beta-blocker
• consider adding an aldosterone antagonist:
• if the patient remains symptomatic
• if the patient is no longer symptomatic but still requires treatment of hypertension Published: 18-Feb-2016 Valid until: 17-Nov-2017 • consider a thiazide diuretic, or switch to a loop diuretic if the patient is already being treated with a thiazide diuretic [2] • consider amlodipine, hydralazine, or felodipine if hypertension persists [2] • other calcium channel blockers should be avoided, particularly verapamil and diltiazem [3] • moxonidine and alpha-adrenoceptor antagonists are not recommended [2] Diabetes and systolic heart failure:
• may increase the progression of heart failure (HF)
• diabetic nephropathy may be prevented by treatment with angiotensin II receptor blockers (ARBs) and possibly ACEI [2] • eplerenone reduces morbidity and mortality in patients with diabetes 3-14 days post myocardial infarction (MI) with LV dysfunction • medication management:
• good glycaemic control should be maintained
• avoid metformin as it increases risk of lactic acidosis in severe or decompensated CHF
• if using metformin:
• monitor renal function
• review the use of metformin if the serum creatinine level is greater than 130micromol/L, or the estimated glomerular filtration rate (eGFR) is less than 45mL/min/1.73m 2 • use as a first-line agent in overweight patients with type 2 diabetes mellitus without significant renal dysfunction
• thiazolidinediones are contraindicated
• non-selective beta-blockers can mask warning signs of hypoglycaemia − a cardioselective beta-blocker is preferred
• some concern has existed over the adverse metabolic effects of beta-blockers in those with diabetes:
• however, cardioselective beta-blockers are not contraindicated in diabetes and are as effective in improving outcome in diabetic patients as in non-diabetic individuals, although different beta-blockers may have different effects on glycaemic indices [2] • refer to diabetes clinic , Peninsula Health
• or private Diabetes educatorFrankston,Mornington, Rosebud,, Hastings 31 REFER to heart failure rehabilitation Quick info:
Heart Failure rehab programs offer a structured, supervised group exercise-based rehabilitation programme designed for patients with heart failure (HF) [1] :
• ensure patient is stable and does not have a condition or device that would preclude an exercise-based rehabilitation programme • include a psychosocial and educational component in the programme • multi-disciplinary cardiac rehab program coordinated by coronary care nurse and exercise physiologist Eligibility: heart failure or acute cardiac event or surgery Hours: • recommended for all patients with HF with systolic heart falure (SHF) [1] • also benefits patients with asymptomatic SHF [7] • slows disease progression, improves exercise capacity, increases ejection fraction, and decreases hospitalisations and mortality [4] • discontinue medications that compromise renal function, ie NSAIDs, calcium-channel blockers, and potassium supplements (see pharmacological management node above) Commencing treatment:
• initiate therapy at a low dose [1] • introduce a beta-blocker if possible and appropriate, increasing to the maximum tolerated therapeutic dose before increasing the ACEI • then titrate the ACEI dose upwards at no more than 2-weekly intervals until a target dose for management, or highest tolerated dose, is achieved [1] • no clinically important differences in efficacy have been demonstrated between ACEI: however, clinical experience recommends the following for use in primary care:
• enalapril-start 2.5mg daily, target 10-20mg twice daily
• lisinopril-start 2.5mg daily, target 20-40mg daily
• ramipril-start 1.25mg daily, target 5-10mg daily
• trandolapril-start 0.5mg daily target 2-4mg daily Consider seeking specialist advice prior to commencing treatment if:
• baseline creatinine is greater than 221micromol/L [5, 7] or estimated glomerular filtration rate (eGFR) of less than 30mL/ min/1.73m 2 [7] • potassium is greater than 5mmol/L [5, 7] • urea is greater than 12mmol/L
• sodium is 130mmol/L or less
• the patient is taking high-dose diuretics (more than 80mg frusemide daily)
• there are concerns about low blood pressure (BP) [6] • the patient is frail and elderly
Adverse effects:
• hypotension may occur with concomitant therapy − if symptomatic:
• discontinue calcium channel blockers and nitrates if at all possible • dry cough:
• may be a symptom of pulmonary oedema
• if the cough is persistent and troubling the patient, an angiotensin II receptor blocker (ARB) may be substituted for the ACE inhibitor • worsening of renal function [3] • hyperkalaemia [3] • angioedema (rarely) [3] Contraindications:
• pregnancy and breastfeeding The Peninsula Pathways Program aims to improve the continuity of patient care between primary, community and hospital care settings in the Frankston-Mornington Peninsula region. Work groups comprising of experienced health professionals (GPs, specialists, nurses, allied health professionals) were established to review and localise pathways.
The objective of this pathway is to improve outcomes for patients with heart failure.
To cite this pathway, use the following format:
Map of Medicine (MoM). Heart Failure. Frankston-Mornington Peninsula Medicare Local View. Melbourne: Map of Medicine; 2015.
Editorial methodology
This pathway is currently the first version localised to Frankston Mornington Peninsula. This pathway has been developed according to the Map of Medicine editorial methodology, using the evidence and expert advice of the international heart failure pathway as a starting point. The content of this care map was further developed with reference to Australian National Heart Foundation guidelines and other current evidence-based guidelines and practice-based knowledge provided by local practitioners with front-line clinical experience (see contributors section of this document).
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